Patient and Physician Perspectives on MSdialog, an Electronic PRO Diary in Multiple Sclerosis by Peter Greiner et al.
ORIGINAL RESEARCH ARTICLE
Patient and Physician Perspectives on MSdialog, an Electronic
PRO Diary in Multiple Sclerosis
Peter Greiner1,4 • Anna Sawka2 • Emma Imison3
Published online: 8 September 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Background MSdialog, a web- and mobile-based soft-
ware application, captures data on self-administration of
subcutaneous interferon b-1a, clinical outcomes, and
patient-reported outcomes in patients with multiple scle-
rosis outside the clinic.
Methods Patient and healthcare professional reactions to
MSdialog were surveyed; participants rated benefits of
MSdialog detailed in an explanatory video. A 6-week pilot
study of patients with multiple sclerosis then assessed
MSdialog usability. After participating in a training tele-
conference, patients completed weekly health reports via
MSdialog, plus two usability surveys (weeks 3 and 6) and
an exploratory follow-up telephone interview.
Results Seventy-six patients, 92 neurologists and 40
multiple sclerosis nurses completed the MSdialog benefits
survey. Highly motivating benefits for patients included
sharing information with healthcare providers and captur-
ing patient-reported outcomes data; healthcare providers
were highly motivated by data availability on patient-re-
ported outcomes and adherence. Thirty-nine of 42 enrolled
patients completed the pilot study. Overall, 87 % of
patients stated that completion of patient-reported out-
comes with MSdialog fitted in ‘‘fairly well’’ to ‘‘extremely
well’’ with their weekly routine. At week 6, 77 % of
patients were ‘‘very satisfied’’ or ‘‘extremely satisfied’’
with their MSdialog experience; 82 % considered it better
than previous methods for tracking their health and 95 %
would recommend using MSdialog. Most patients were
highly motivated to use MSdialog; reasons given included
‘‘helps me remember what to mention to my doctor’’.
Conclusion MSdialog was considered easy to use and
superior to patients’ previous methods for tracking health.
The ability to provide valuable data to healthcare providers
offers the potential to improve patient–physician commu-
nication and engagement.
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Key Points for Decision Makers
MSdialog was considered to be easy to use and to
provide valuable patient-reported outcome and
adherence data to healthcare providers, offering the
potential to improve the management of patients
with MS.
Highly motivating benefits for the use of MSdialog
for both patients and healthcare providers included
sharing information and capturing patient-reported
outcomes and adherence data, enabling patients to
actively engage in the management of their disease
between consultations, as well as during
consultations and decision making.
Of 39 patients, 82 % considered MSdialog better
than previous methods for tracking their health and
95 % would recommend its use.
1 Introduction
Multiple sclerosis (MS) is a chronic, demyelinating disease
associated with progressive neurodegeneration and neuro-
logical disability, affecting an estimated 2.5 million people
worldwide [1]. Many patients with MS report a multitude
of symptoms, including pain, fatigue, sleep disturbances,
depression, and bladder/bowel dysfunction. These patient-
reported outcomes (PROs) can have a negative effect on
patients’ health-related quality of life (HRQoL) [2].
Objective measures of MS, such as the Expanded Dis-
ability Status Scale, which is biased towards the mea-
surement of the patient’s locomotor function, do not always
reflect the patient’s experience of the disease, sometimes
leading to a lack of holistic care [2]. Furthermore, in the
limited time that doctors and patients have together and
because of ineffective communication [3], it is not always
possible to identify all the issues that are important in the
management of MS.
Effective management of MS-related symptoms such as
pain, fatigue, and sleep disturbances requires patient-cen-
tered care [4] and effective communication between
patients and their healthcare professionals (HCPs). Indeed,
the relationship between patients and physicians is strongly
associated with patient satisfaction and adherence to
treatment [5, 6], and physician–patient communication has
been shown to be central to improving adherence to long-
term therapy and achieving optimal long-term treatment
outcomes [7, 8]. However, approximately 50 % of patients
with MS have been shown to discontinue treatment after
6 years [9]. Moreover, patients’ and physicians’ percep-
tions of the underlying reasons for nonadherence may
differ; in the MS Choices Survey, 82 % of physicians cited
side effects as the main reason for nonadherence, while
only 42 % of patients gave the same reason [10]. Despite
the importance of patient–physician communication, the
Profile Project survey demonstrated that although 79 % of
neurologists believe their communication is adequate and
competent at the point of MS diagnosis, only 14 % believe
they are able to manage all the needs and expectations of
their patients [3]. This finding indicates that improving
physician–patient communication, an important part of
self-care, may enhance the long-term management of
patients with MS should adequate resource and time be
available.
Disease information materials, decision aids, and edu-
cational interventions, such as coaching and question
prompts for patients and communication skills training for
HCPs, have been shown to increase patient knowledge and
empower patients to engage in their disease management
[11, 12]. Patient support programs can improve patient
adherence to treatment [13] and reduce hospitalization
rates [14], and patients find these support programs highly
valuable at all stages of their disease [15].
A number of tools have recently been developed to
facilitate patient-centered care and PRO assessment,
including Tecficare (Biogen Idec, Cambridge, MA, USA),
an application (App) developed specifically for patients
taking dimethyl fumarate; Betaconnect
TM
(Bayer Health-
Care, Leverkusen, Germany; an electronic autoinjector
device with Bluetooth and USB capabilities) and an asso-
ciated software system, myBETAappTM (Bayer Health-
Care, Leverkusen, Germany) for administering and
monitoring interferon (IFN) b-1b; and MSdialog (Merck
Serono, Darmstadt, Germany).
MSdialog is a web- and mobile (i.e., cell phone and
tablet)-based software application that combines informa-
tion from RebiSmart (Merck Serono; a handheld elec-
tronic autoinjector for the subcutaneous [sc] administration
of IFN b-1a with wireless data transmission capabilities)
with health information recorded by patients via their
personal computer or smartphone to collect and store real-
time data regarding administration, clinical outcomes, and
PROs (Fig. 1) [16]. There are also future plans to broaden
the use of MSdialog to work with other devices (e.g.,
RebiDose [Merck Serono]). MSdialog offers a practical
means by which patients record and exchange information
with their MS HCP (MS specialists/neurologists and nur-
ses), with the aim of supporting the patient–physician
relationship and offering patients a method of engaging in
the management of their MS [16]. Haase et al. have shown
that the majority of patients with MS use computers and
mobile phones regularly, and approximately 90 % of
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patients are competent to use electronic health records and
patient relationship management systems [17].
MSdialog uses existing standardized and validated PRO
instruments that have been used in previous research [16].
MSdialog was designed to be flexible regarding the num-
ber, type, and frequency of PRO questions in order to align
clinical assessments with individual patient needs. PRO
instruments were included in MSdialog to help patients
with MS engage with their disease. PRO instruments for
inclusion were identified through structured workshops
with international representation from MS patients, clinical
nurses, and neurologists from Sweden, the UK, and Canada
[16].
Herein, we report the results of a survey assessing the
most important product benefits of MSdialog from both the
patients’ and physicians’ perspectives, and a subsequent
pilot study exploring the usability of MSdialog in patients
with MS.
2 Methods
2.1 Study Designs and Data Collection
2.1.1 MSdialog Benefits Survey
Patients with MS from the UK and Canada, and HCPs (MS
specialists/neurologists [hereafter referred to as
‘neurologists’] and nurses) involved in the management
and treatment of MS patients, were recruited to take part in
an MSdialog survey between June and July 2013 (see
electronic supplementary material). Patients were identified
from an internally held database by EMD Serono, Inc.,
Rockland, MA, USA. Patients from the UK and Canada
were sent a letter from MySupport (a service developed by
Merck Serono to support patients who are prescribed sc
IFN b-1a) and EMD Serono, respectively, outlining details
of the study, and were asked to register their interest via a
webpage. HCPs were recruited from an online panel, which
they previously provided consent to join, and were asked to
access a webpage to opt into the survey. HCPs who opted
in were selected for relevance via initial screening ques-
tions. A small financial incentive was offered to partici-
pants to take part in and complete the survey. Participants
viewed an MSdialog explanatory video and completed a
15-min online questionnaire on their overall reaction to
MSdialog. Product benefits were ranked on a scale of 1–7,
with 7 being the most positive response and 1 being the
least positive.
2.1.2 Patient Usability Pilot Study
Patients with MS from the UK and Canada, who were
current or previous RebiSmart users, and who had taken
part in the MSdialog survey and provided permission for
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My Profile Resources Help Log Out
Fig. 1 MSdialog graphs representing sample results for selected
patient-reported outcomes (line chart in upper half of figure) and
treatment adherence (bar chart in lower half of figure) in the
healthcare professional view. Names and personal details in figure are
fictitious and for illustrative purposes only. Displaying the EDSS
score in the MSdialog graphs is optional and the EDSS score data are
not included in the figure
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pilot study. An incentive was offered to patients to take
part in and complete the study (UK, £215; Canada, $380).
The study consisted of the following stages: registration
and setting up an MSdialog account; completion of a 5-min
online survey entitled ‘‘Me and My MS’’ to gather con-
textual data around treatment and disease history and to
ascertain early levels of interest in MSdialog; a short
MSdialog training teleconference; weekly health reports
for 6 weeks that were completed via MSdialog, which
formed the basis of the usability pilot study; and comple-
tion of a 5-min usability survey at weeks 3 and 6. A 30-min
exploratory follow-up telephone interview was completed
in a subset of randomly selected patients; patients were not
selected using patient characteristics or survey answers,
and participation was based on the patient providing prior
consent to participate and their availability to attend the
telephone interview.
For the weekly health reports, patients were randomly
assigned (i.e., independent of any patient factors) to com-
plete either one MS quality-of-life (QoL) questionnaire
consisting of 31 questions, or five short questionnaires on
pain (6 questions), cognitive function (5 questions), fatigue
(5 questions), mental health (5 questions), and social sup-
port (5 questions).
All patients who participated in the study were required
to try to provide feedback on the MSdialog web-based
software via the 5-min usability survey at weeks 3 and 6
and, in a subset of patients, a 30-min exploratory follow-up
telephone interview. Testing and providing feedback on the
mobile App was optional and the choice of the individual
patient.
2.1.3 Ethics
Because of the non-experimental design of this study (a
survey and telephone interview designed and conducted
solely to judge benefits of the MSdialog software appli-
cation among participants who use or deliver the applica-
tion), ethics approval was not required, and no ethics
committees were approached prior to beginning the study.
All interactions with participants took place over the tele-
phone. There was no change to the medical management of
patients, and no randomization of participants to different
groups. There were no specific questions relating to par-
ticipants’ health other than the length of time since MS
diagnosis and their method, attitudes, or satisfaction with
tracking health status; MSdialog itself included approved
health-related questions which participants completed as
part of testing the usability of MSdialog, but this data was
not captured and was not the focus of the study. All data
and survey responses were anonymized before analysis,
and contact details of patients participating in telephone
interviews deleted. All patients provided written informed
consent, and could opt out of the survey at any time.
3 Results
3.1 MSdialog Survey
3.1.1 Patient and HCP Demographics
In total, 76 patients (UK 35; Canada 41), 92 neurologists
(UK 52; Canada 40), and 40 MS nurses (UK 20; Canada
20) completed the MSdialog benefits survey. Patient and
HCP baseline demographics are shown in Tables 1 and 2,
respectively.
3.1.2 Overall Reaction to MSdialog
Patients expressed a high interest in using MSdialog, with
94 % of patients rating ‘‘how would you describe your
level of interest in using the MSdialog software tool’’ as
5–7 (where 7 is ‘‘very interested’’ and 1 is ‘‘not at all
interested’’). Patient quotes included ‘‘I think it is awesome
and I would like to try it’’ and ‘‘I try to remember to write
down how I’m feeling…but this is in a diary at home and I
sometimes forget…if there was a tool available to do this
on-the-go it would help’’. HCPs also appreciated the ability
of patients to record information, with one UK neurologist
stating ‘‘This is an excellent tool, it engages patients more
with their treatment and provides valuable sources of
information for the treating neurologist’’. HCP quotes also
included ‘‘…it seems to be a good idea, it could save me
time and help focus on patient needs’’ and ‘‘Great! Should
decrease amount of time on asking questions. Will
streamline appointments and make it easier to set realistic
goals that are mutually acceptable to HCPs and patients’’.
3.1.3 The Value of MSdialog—User-Reported Benefits
In general, user-reported benefits were highly motivating
for patients, scoring 6.0–6.3 out of 7 on all but one benefit
tested. The most motivating benefit related to sharing
information with their doctor: 71 % of patients ranked this
among their top three most motivating benefits. In total,
over 80 % of patients agreed that MSdialog could deliver
on each of the benefits listed in Fig. 2, with the exception
of ‘‘MSdialog would keep me motivated to take my drug’’.
Ninety-six percent of patients agreed with the benefit
‘‘MSdialog would be an easy way to provide relevant
information to my doctor’’, rating this benefit 5–7 on the
7-point scale; and 92 % of patients agreed ‘‘MSdialog
would be an easy way for me to engage in the management
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of my disease’’, rating this statement 5–7 on the 7-point
scale.
In alignment with the views of the patients sur-
veyed,[80 % of HCPs were highly motivated (i.e.,
recorded 5–7 on the 7-point scale) by the availability of
PRO data, identifying areas to focus on during consulta-
tions and helping patients to engage with their disease.
Neurologists were also particularly motivated by the
availability of adherence data, with 48 % of neurologists
most motivated by the statement ‘‘MSdialog would provide
readily available, user-friendly patient treatment adherence
data over time’’. Over 80 % of HCPs agreed with the
statements ‘‘MSdialog would provide readily available,
user-friendly patient treatment adherence data over time’’
and ‘‘MSdialog would provide readily available, user-
friendly, agreed upon patient-reported outcome data over
time’’, giving mean ± standard deviation (SD) scores of
5.7 ± 1.3 out of 7 ± 1.2 (with 7 being ‘‘completely agree’’
and 1 being ‘‘completely disagree’’) for both statements.
HCPs were least convinced by the benefit that MSdialog
Table 1 Participant demographics in MSdialog benefit testing
Demographic UK (n = 35) Canada (n = 41) Total (n = 76)
Age
18–40 years 12 (34) 18 (44) 30 (39)
41–50 years 17 (49) 16 (39) 33 (43)
[50 years 6 (17) 7 (17) 13 (17)
Female 25 (71.4) 27 (65.9) 52 (68.4)
Male 10 (28.6) 14 (34.1) 24 (31.6)
Number of times seen by a neurologist per yeara (mean ± SD) 1.9 ± 1.2 1.6 ± 0.8 1.8 ± 1.0
Number of times seen by a nurse per yeara (mean ± SD) 3.5 ± 0.4 0.8 ± 0.2 2.1 ± 0.3
Data are shown as n (%) unless otherwise indicated
SD standard deviation
a Visit concerning multiple sclerosis
Table 2 Healthcare professional demographics in MSdialog benefit testing














B40 years 20 (38) 4 (20) 3 (8) 3 (15) 23 (25) 7 (18)
[41 years 32 (62) 16 (80) 37 (92) 17 (85) 69 (75) 33 (82)
Patients that they see, manage, and train regarding DMDs in an average month
8–30 35 (68) 15 (75) 17 (42) 5 (25) 52 (56) 20 (50)
31–50 10 (19) 5 (25) 8 (20) 6 (30) 18 (20) 11 (27)
[50 7 (14) 0 15 (38) 9 (45) 22 (24) 9 (23)
Attitude towards adopting new technologiesa
Early adopter 36 (69) 15 (75) 30 (75) 18 (90) 66 (72) 33 (82)
Early majority 16 (31) 5 (25) 10 (25) 2 (10) 26 (28) 7 (18)
Level of RebiSmart knowledge
Very/somewhat familiar 41 (79) 20 (100) 40 (100) 19 (95) 81 (88) 39 (97)
Heard of/seen device 11 (21) 0 0 1 (5) 11 (12) 1 (3)
Data are shown as n (%)
DMD disease-modifying drug
a Self-defined based on which statement best described them: early adopters defined themselves as ‘‘always one of the very first physicians to use
new innovative technologies or services’’ or ‘‘usually adopting new innovative technologies or services quite quickly and certainly before the
majority of your colleagues are using them’’; early majorities defined themselves as ‘‘slightly more conservative than some of your colleagues,
taking time to form your opinion and relying heavily on the opinions of others before adopting a new innovative technology or service’’
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could save time during consultations, giving a mean ± SD
score of 5.0 ± 1.5 out of 7.
3.1.4 The Value of MSdialog—Functionality Benefits
Overall, the functionality benefits of MSdialog were
appealing to at least 80 % of patients, and a high propor-
tion (C54 %) found most benefits to be ‘‘extremely
appealing’’ (Fig. 3). The most appealing benefit for
patients was the ability to share how MS is impacting their
life.
Similar to the opinions of the patients, surveyed HCPs
also found all functionality benefits appealing. All benefits
appealed to C73 % of neurologists, C78 % of nurses,
and C74 % of all HCPs, irrespective of role. Viewing
adherence and PRO data was the most appealing function.
The highest performing benefit for nurses related to
MSdialog allowing patients to set reminders on their future
appointments, medication and treatments, and the PRO
questionnaires.
3.1.5 The Value of MSdialog—PROs
Patients felt that it was highly important to monitor and
review PROs over time, with more than 90 % of patients
scoring the following between 5 and 7 (with 7 being
‘‘extremely important’’ to monitor and 1 being ‘‘not
important at all’’): fatigue (99 %), fatigue impact (97 %),
physical health (96 %), general health (95 %), cognitive
deficits (93 %), pain (91 %), and sleep quality (91 %).
Symptoms such as bowel control and sexual satisfaction
were considered less important, with only 70 and 65 % of
patients scoring them between 5 and 7, respectively.
HCP responses generally agreed with those of patients
regarding the importance of monitoring PROs, but also
placed higher emphasis on mental (92 % [HCP] vs 81 %
[patient]), emotional (91 vs 80 %), and social (92 vs 73 %)
well-being. When patients and HCPs were asked about
other health considerations or PROs that they felt were
important to monitor with MSdialog, both stated treatment
side effects (e.g., injection-site reactions and flu-like
symptoms); gait, balance, and mobility; work/employment
capacity; dizziness/numbness; relationships; QoL; and
relapses.
3.1.6 The Value of MSdialog—Clinical Benefits
The assessment of clinical benefits was carried out by
HCPs only. Neurologists and nurses exhibited a high level
of agreement regarding clinical benefits relating to treat-
ment adherence. Ninety-three percent of HCPs agreed (i.e.,
recorded 5–7 on the 7-point scale) with the claim that
engaged patients are more adherent (mean ± SD score:
6.0 ± 0.9 out of 7) and 91 % agreed that better adherence
generally leads to better clinical outcomes (mean ± SD
score: 5.9 ± 1.0 out of 7).
Would be an easy way to provide
relevant information to my doctor 
Would allow me and my doctor to
make more informed decisions
about my treatment management  
Would be a way to help better
utilize the time I have with
my doctor  
Looks easy to use
Completely disagree (1)
Would be an easy way for me to
engage in the management of
my disease  
Would help me have more
informed conversations with
my doctor  
Would aid remote consultations/
calls with my doctor or nurse in
between visits 
Would keep me motivated to take
my drug 



































Fig. 2 Percentage of patients
who believe MSdialog would
deliver benefits. Patients were
asked: ‘‘Please indicate the
extent to which you agree or
disagree with the following
statements’’. Percentages do not
always total 100 % due to
rounding
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3.2 MSdialog Usability Pilot Survey
3.2.1 Patient Demographics and MS History
A total of 42 patients who completed the MSdialog survey
were enrolled in the MSdialog usability pilot survey, of
whom 39 completed the week 6 health report and feedback
survey (UK 19 patients; Canada 20 patients) and 12 com-
pleted the exploratory follow-up telephone interview (six
each from the UK and Canada). Two patients discontinued
from the study because of illness and one patient discon-
tinued for unknown reasons. Of the 39 patients who trialed
and provided feedback on the MSdialog web-based soft-
ware, 13 patients also chose to use the mobile App.
The mean ± SD age of patients taking part in the pilot
study was 43.9 ± 7.6 years and 72 % of patients were
women. Concerning disease and treatment history, the
mean ± SD time since diagnosis was 7.0 ± 6.4 years and
mean ± SD duration of drug treatment was
4.8 ± 4.5 years. Most patients (82 %) were currently
receiving sc IFN b-1a; other current MS therapies were
dimethyl fumarate (8 %), other (10 %), and none (10 %).
Previous treatments included sc IFN b-1a (15 %) and
intramuscular IFN b-1a (13 %).
3.2.2 Current and Previous MS Management
Overall, the mean ± SD frequency of interaction with a
neurologist or nurse was 1.5 ± 0.7 and 1.6 ± 1.6 times per
year, respectively. Patients reported moderate-to-high sat-
isfaction with MS management (mean ± SD score:
5 ± 1.5 out of 7 on the 7-point scale).
Generally, motivation to track health status was high:
79 % of patients scored their motivation as 5–7, where 7
indicates ‘‘extremely motivated’’ and 1 ‘‘extremely unmo-
tivated’’. In total, 63 % of patients were dissatisfied with
their current tracking tool, rating their current tool from
1–4, where 1 indicates ‘‘extremely dissatisfied’’ and 7
indicates ‘‘extremely satisfied’’. Sixty-four percent of
patients reported previously keeping a record of their
health. Pen and paper was the most common previously
used method to keep health records (92 %), followed by
mobile phone Apps and other online tools (both 8 %), and
blogs and other electronic formats (both 4 %). Most





























Allows you and your doctor to
agree together which PRO
questionnaires are relevant for
you to complete   
Allows you to create outcome
reports based on your perception
and share them with your doctor
and/or nurse   
Allows you to review your
treatment adherence and PROs 
Allows you to share how your
MS is impacting your life 
Allows your doctor to review
your treatment adherence and
your PROs at the same time  
Allows you and your doctor
and/or nurse to view treatment
adherence reports  
Allows you to set reminders on
your future appointments,
medication and treatments,
and PRO questionnaires   
Allows you to see which
medications you are to take,
when and in which dosing  
47201884 5.9
Allows you to view and add
reference materials or links to
reference materials  
55161385 5.9
Offers a calendar function for you
and your nurse to schedule visits
and when to take medication or
complete reports   
Fig. 3 Percentage of patients
that found each functional
MSdialog benefit appealing.
Patients were asked: ‘‘Please
indicate how appealing you find
each of the following
statements’’. Percentages do not
always total 100 % due to
rounding. PRO patient-reported
outcome
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patients (64 %) stated that they often or always forget to
mention something they intended to raise with their HCP
during their consultation. Furthermore, 51 % of patients
reported often or always feeling they could have made
better use of their consultation time.
3.2.3 Patient Feedback on MSdialog Web and App
Platforms
Usability (overall ease of use) of MSdialog increased from
week 3 to week 6, with the percentage of patients finding
the web-based software ‘‘easy’’ or ‘‘very easy’’ to use,
increasing from 77 % at week 3 to 85 % at week 6. For the
13 patients who used the MSdialog App, 85 % found it
‘‘easy’’ or ‘‘very easy’’ to use at both week 3 and week 6.
Sixty-four percent of patients found the overall intuitive-
ness of the web-based software ‘‘easy’’ or ‘‘very easy’’ at
week 6, compared with 59 % at week 3; the corresponding
values for the App were 85 and 69 %. Importantly, overall
ease of PRO completion also improved over time. At week
6, 95 % of patients found PRO completion using the web-
based software ‘‘easy’’ or ‘‘very easy’’, compared with
85 % at week 3, while the same parameter increased from
92 to 100 % for the App.
Eighty-seven percent of patients stated that PRO com-
pletion fitted in ‘‘fairly well’’ to ‘‘extremely well’’ with
their weekly routine, with 44 % able to complete the
questionnaire within 6–10 min. The mean ± SD time spent
completing the questionnaires was 11.3 ± 5.2 min per
week. At week 3, 69 and 79 % of patients were either
‘‘extremely committed’’ or ‘‘committed’’ to completing
health reports on a weekly or monthly basis, respectively.
At week 6, this decreased to 64 and 74 %, respectively.
Patients considered all six health reports completed in the
study useful to monitor, with the longer MS QoL report
rated as the most important (mean ± SD score: 6.1 ± 1.0
out of 7, where 7 is ‘‘most useful’’ and 1 is ‘‘least useful’’),
followed by pain (5.9 ± 1.2), cognitive function
(5.9 ± 1.3), fatigue (5.8 ± 1.4), mental health (5.7 ± 1.2),
and social support (5.2 ± 1.5). An exploratory follow-up
of a small patient sample (n = 12) found that the utility of
PRO health reports was dependent on the individual:
patients placed highest value on the PROs that they expe-
rience. However, some patients considered certain PROs to
be less relevant to their circumstances and thus challenging
to answer questions on, while others considered it useful to
highlight less recognized issues.
At week 6, 77 % of patients were ‘‘very satisfied’’ or
‘‘extremely satisfied’’ with their MSdialog experience so
far, with 82 % considering it a better method for tracking
their MS health compared with previously tried methods,
and 95 % of patients stating that they would recommend
MSdialog to another person with MS. At the start of the
study (week 0), interest in MSdialog was high: 74 % of
patients recorded scores of 6 or 7 (with 7 being ‘‘ex-
tremely interested’’ and 1 ‘‘extremely uninterested’’). This
high initial interest was sustained and increased slightly
over the course of the pilot study, with 85 % of patients
returning a score of 6 or 7 at week 6. Similarly, most
patients were highly motivated to use MSdialog to track
health: 95 % of patients recorded a score of 5–7 and 82 %
a score of 6–7, with 7 being ‘‘extremely motivated’’. The
most important reasons for high motivation in over 50 %
of patients at week 6 were ‘‘helps me remember what to
mention to my doctor’’, ‘‘easy way to engage in disease
management’’, and ‘‘easy way to provide relevant infor-
mation to doctor’’.
4 Discussion
The benefits survey and pilot study described herein were
designed to assess patients’ and physicians’ perceptions of
the potential value and usability of MSdialog. The MSdi-
alog benefits survey highlighted the value that MSdialog
may bring to the management and care of patients with
MS. Both patients and physicians felt that MSdialog would
improve the sharing of information. Physicians were highly
motivated by the availability of PRO data and engaging
patients with their disease. The MSdialog usability pilot
study found the usability to be high. Patients reported both
the MSdialog web-based software and the App to be easy
to use, with ease of use increasing over 6 weeks. Patients
were highly committed to reporting PROs on a weekly or
monthly basis and most patients found MSdialog to be a
better method of tracking their health than their current
method.
The findings reported here demonstrate that MSdialog
provides a user-friendly tool for patients to monitor their
own health status, thus engaging with the management of
their MS, and to share this information with their HCP. The
inclusion of patient-centered care in routine MS assess-
ments through a tool such as MSdialog provides physicians
with information that they might not otherwise have access
to, which may optimize HRQoL and overall outcomes.
Indeed, optimizing use of time with HCPs was recognized
as an area of need in the benefit testing survey. Considering
that the usability pilot study found that[60 % of patients
forget to tell their physician something regarding their
health during consultations, there is a clear need for sys-
tems that facilitate the sharing of information between
patients and their HCPs. It has previously been reported
that the patients’ ability to effectively communicate with
their HCPs is an essential part of self-care [8], yet our
findings suggest that this remains a problem for many
patients. In both the pilot study and the MSdialog benefit
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survey, patients identified the effective sharing of relevant
data with their HCPs as a highly motivating/appealing
benefit of MSdialog. Thus, a tool such as MSdialog that
captures data on PROs between consultations has the
potential to improve the flow of information from patients
to their HCPs by identifying key areas to focus on during
consultations. Providing HCPs with such data will allow
them to consider PROs alongside clinical assessments,
magnetic resonance imaging scans, and adherence data
from injection devices when assessing the effectiveness of
treatment, making treatment decisions, and identifying
treatment problems and educational needs. In addition,
both neurologists and nurses felt that the data obtained
from MSdialog would provide a focus point for their
consultations and could enhance patient participation in
decision making.
The data from this pilot study and MSdialog benefit
survey contribute to the understanding of the potential
role of MSdialog in optimizing the management of MS;
however, certain limitations should be acknowledged.
Patients and physicians recruited to take part in both
surveys were from the UK and Canada only, and this
small pool of participants may not accurately represent
patient and physician perspectives globally. Patients were
offered a financial incentive to take part in the usability
pilot study and the MSdialog benefit survey, and this
small incentive may introduce a positive bias in terms of
the survey answers and retention rates, which should be
interpreted with caution. Furthermore, patients motivated
to participate in this type of research include those who
appreciate the use of computers, applications, and com-
pleting questionnaires, and our data may not represent the
wider patient population as a whole; as such, patients with
MS who did not participate in the survey may have
responded differently. Concerning the usability study
specifically, patients did not have access to the full
functionality of MSdialog; although they could explore
other features, the basis for participation in the study was
completion of the health reports. Discontinuation rates
were low in the 6-week usability pilot study, although it is
not clear whether participation may decrease in studies
with a longer duration. Importantly, in the benefit testing
survey, HCPs and patients watched a video explaining
MSdialog but did not have access to the tool and, there-
fore, were evaluating MSdialog without hands-on expe-
rience or the training they would have received in the
clinical setting. Finally, patients were identified and
approached from a list of RebiSmart users provided by
EMD Serono (a subsidiary of Merck KGaA, Darmstadt,
Germany); although there was no preselection of patients,
this process may further limit the applicability of our
findings to the wider MS population.
5 Conclusion
MSdialog was considered to be easy to use and to provide
valuable PRO and adherence data to HCPs, offering the
potential to improve the management of patients with MS.
In addition, the findings suggest that patients felt MSdialog
would help them to actively engage in the management of
their disease between consultations, as well as during
consultations and decision making, through improved
communication with their healthcare team. MSdialog pro-
vides a good example of the potential development of
healthcare by providing patients and physicians with a tool
to enhance disease management.
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